Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

I agree with you staccani. For me it all boils down to NASH cirhossis and NASH fibrosis. Big pharma is gunning for it. Gilead bought up like 2 or 3 small cap biotechs, Allergan paid $1.7B to buy Tobira. Conatus is still risky but you are right the risk/reward is amazing. Sure if the trial results aren't good the stock could lose as much as $4 per share right now, but if it is successful you are talking about $200 to $500 per share. Well worth the risk IMO.